Biopoin

Country: Unjoni Ewropea

Lingwa: Ingliż

Sors: EMA (European Medicines Agency)

Ixtrih issa

Ingredjent attiv:

epoetin theta

Disponibbli minn:

Teva GmbH

Kodiċi ATC:

B03XA01

INN (Isem Internazzjonali):

epoetin theta

Grupp terapewtiku:

Other antianemic preparations

Żona terapewtika:

Kidney Failure, Chronic; Anemia; Cancer

Indikazzjonijiet terapewtiċi:

Treatment of symptomatic anaemia associated with chronic renal failure in adult patients.Treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.

Sommarju tal-prodott:

Revision: 15

L-istatus ta 'awtorizzazzjoni:

Authorised

Data ta 'l-awtorizzazzjoni:

2009-10-23

Fuljett ta 'informazzjoni

                                54
B. PACKAGE LEAFLET
55
PACKAGE LEAFLET: INFORMATION FOR THE USER
BIOPOIN 1,000 IU/0.5 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
BIOPOIN 2,000 IU/0.5 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
BIOPOIN 3,000 IU/0.5 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
BIOPOIN 4,000 IU/0.5 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
BIOPOIN 5,000 IU/0.5 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
BIOPOIN 10,000 IU/1 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
BIOPOIN 20,000 IU/1 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
BIOPOIN 30,000 IU/1 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
epoetin theta
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Biopoin is and what it is used for
2.
What you need to know before you use Biopoin
3.
How to use Biopoin
4.
Possible side effects
5.
How to store Biopoin
6.
Contents of the pack and other information
7.
Information for injecting yourself
1.
WHAT BIOPOIN IS AND WHAT IT IS USED FOR
WHAT BIOPOIN IS
Biopoin contains the active substance epoetin theta, which is almost
identical to erythropoietin, a
natural hormone produced by your body. Epoetin theta is a protein
produced by biotechnology. It
works in exactly the same way as erythropoietin. Erythropoietin is
produced in your kidneys and
stimulates your bone marrow to produce red blood cells. Red blood
cells are very important for
distributing oxygen within your body.
WHAT BIOPOIN IS USED FOR
Biopoin is used for the treatment of anaemia accompanied by symptoms
(for example 
                                
                                Aqra d-dokument sħiħ
                                
                            

Karatteristiċi tal-prodott

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Biopoin 1,000 IU/0.5 ml solution for injection in pre-filled syringe
Biopoin 2,000 IU/0.5 ml solution for injection in pre-filled syringe
Biopoin 3,000 IU/0.5 ml solution for injection in pre-filled syringe
Biopoin 4,000 IU/0.5 ml solution for injection in pre-filled syringe
Biopoin 5,000 IU/0.5 ml solution for injection in pre-filled syringe
Biopoin 10,000 IU/1 ml solution for injection in pre-filled syringe
Biopoin 20,000 IU/1 ml solution for injection in pre-filled syringe
Biopoin 30,000 IU/1 ml solution for injection in pre-filled syringe
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Biopoin 1,000 IU/0.5 ml solution for injection in pre-filled syringe
One pre-filled syringe contains 1,000 international units (IU) (8.3
µg) epoetin theta in 0.5 ml solution
for injection corresponding to 2,000 IU (16.7 µg) epoetin theta per
ml.
Biopoin 2,000 IU/0.5 ml solution for injection in pre-filled syringe
One pre-filled syringe contains 2,000 international units (IU) (16.7
µg) epoetin theta in 0.5 ml solution
for injection corresponding to 4,000 IU (33.3 µg) epoetin theta per
ml.
Biopoin 3,000 IU/0.5 ml solution for injection in pre-filled syringe
One pre-filled syringe contains 3,000 international units (IU) (25
µg) epoetin theta in 0.5 ml solution
for injection corresponding to 6,000 IU (50 µg) epoetin theta per ml.
Biopoin 4,000 IU/0.5 ml solution for injection in pre-filled syringe
One pre-filled syringe contains 4,000 international units (IU) (33.3
µg) epoetin theta in 0.5 ml solution
for injection corresponding to 8,000 IU (66.7 µg) epoetin theta per
ml.
Biopoin 5,000 IU/0.5 ml solution for injection in pre-filled syringe
One pre-filled syringe contains 5,000 international units (IU) (41.7
µg) epoetin theta in 0.5 ml solution
for injection corresponding to 10,000 IU (83.3 µg) epoetin theta per
ml.
Biopoin 10,000 IU/1 ml solution for injection in pre-filled syringe
One pre-filled syringe contains 10,000 international units (IU) (8
                                
                                Aqra d-dokument sħiħ
                                
                            

Dokumenti f'lingwi oħra

Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Bulgaru 27-09-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Bulgaru 27-09-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Spanjol 27-09-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Spanjol 27-09-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ċek 27-09-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Ċek 27-09-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Daniż 27-09-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Daniż 27-09-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ġermaniż 27-09-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Ġermaniż 27-09-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Ġermaniż 16-12-2009
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Estonjan 27-09-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Estonjan 27-09-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Estonjan 16-12-2009
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Grieg 27-09-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Grieg 27-09-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Franċiż 27-09-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Franċiż 27-09-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Franċiż 16-12-2009
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Taljan 27-09-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Taljan 27-09-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Latvjan 27-09-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Latvjan 27-09-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Litwanjan 27-09-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Litwanjan 27-09-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Litwanjan 16-12-2009
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Ungeriż 27-09-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Ungeriż 27-09-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Ungeriż 16-12-2009
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Malti 27-09-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Malti 27-09-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Olandiż 27-09-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Olandiż 27-09-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Olandiż 16-12-2009
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Pollakk 27-09-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Pollakk 27-09-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Portugiż 27-09-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Portugiż 27-09-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Portugiż 16-12-2009
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Rumen 27-09-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Rumen 27-09-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Slovakk 27-09-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Slovakk 27-09-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Sloven 27-09-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Sloven 27-09-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Finlandiż 27-09-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Finlandiż 27-09-2023
Rapport ta 'Valutazzjoni Pubblika Rapport ta 'Valutazzjoni Pubblika Finlandiż 16-12-2009
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Svediż 27-09-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Svediż 27-09-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Norveġiż 27-09-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Norveġiż 27-09-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Iżlandiż 27-09-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Iżlandiż 27-09-2023
Fuljett ta 'informazzjoni Fuljett ta 'informazzjoni Kroat 27-09-2023
Karatteristiċi tal-prodott Karatteristiċi tal-prodott Kroat 27-09-2023

Fittex twissijiet relatati ma 'dan il-prodott

Ara l-istorja tad-dokumenti